Boehringer Ingelheim Lilly | PCDS National | Diabetes on the Net

Your web browser is out of date.

For your security and improved experience online, please update your browser.

Diabetes on the Net is intended for healthcare professionals

Company Profile

In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance that centres on compounds representing several of the largest diabetes treatment classes. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributing to the alliance. The Alliance leverages the strengths of two of the world’s leading pharmaceutical companies to focus on patient needs. By joining forces, the companies demonstrate their commitment, not only to the care of people with diabetes, but also to investigating the potential to address areas of unmet medical need

The Boehringer Ingelheim and Lilly Diabetes Alliance has provided the funding for this promotional meeting, including speaker honoraria and presentation support where applicable

Click here for prescribing Information and adverse event reporting (UK) JARDIANCE (empagliflozin)

Click here for prescribing information and adverse event reporting (IE) JARDIANCE (empagliflozin)

The multiple effects of SGLT2 inhibitors on the Cardio–Renal–Metabolic system in type 2 diabetes

This promotional video presentation was originally broadcast on 6 November 2020. Please note that the speakers are not able to answer questions from attendees watching the video on-demand.


Improving cardiovascular outcomes in type 2 diabetes with SGLT2 inhibitors – What is the role of the cardiologist? videos.

PC-GB-103149 | Date of prep: November 2020 

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.